Lineage Cell Therapeutics, Inc. Class of Warrant or Right, Outstanding
Lineage Cell Therapeutics, Inc. (LCTX) had Class of Warrant or Right, Outstanding of 35.18 million shares as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Other Liabilities
us-gaap:ClassOfWarrantOrRightOutstanding · last filed 2026-08-06
- 2026-06-30: Class of Warrant or Right, Outstanding 35.18M shares.
- 2026-03-31: Class of Warrant or Right, Outstanding 35.18M shares.
- 2025-12-31: Class of Warrant or Right, Outstanding 41.10M shares.
- 2024-12-31: Class of Warrant or Right, Outstanding 33.16M shares.
| Period end | Class of Warrant or Right, Outstanding |
|---|---|
| 2026-06-30 | 35.18M shares 10-Q · filed 2026-08-06 |
| 2026-03-31 | 35.18M shares 10-Q · filed 2026-05-12 |
| 2025-12-31 | 41.10M shares 10-Q · filed 2026-08-06 |
| 2024-12-31 | 33.16M shares 10-K · filed 2026-03-05 |
| 2023-12-31 | 0.00 shares 10-K · filed 2026-03-05 |
| 2013-09-30 | 1.75M shares 10-Q · filed 2013-11-12 |
| 2013-06-30 | 1.75M shares 10-Q · filed 2013-08-09 |
| 2013-03-31 | 816.61K shares 10-Q · filed 2013-05-10 |
| 2012-12-31 | 556.61K shares 10-Q · filed 2013-11-12 |
| 2012-09-30 | 556.61K shares 10-Q · filed 2012-11-09 |
| 2012-06-30 | 636.61K shares 10-Q · filed 2012-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |